Viral shedding

Oncolytic viruses, which include both naturally occurring wild-type viruses/attenuated viruses and genetically modified viruses, have recently been developed for use in innovative cancer therapies. Genetically modified oncolytic viruses possess the unique ability to replicate conditionally as a unique gene therapy product. Since oncolytic viruses exhibit prolonged persistence in patients, viral shedding and transmission to third parties should be major concerns for clinical trials along with the clinical safety and efficacy.

Shedding is linked to biodistribution studies but unlike biodistribution, which describes how a product is spread within the animal model’s or patient’s body from the site of administration, shedding describes how it is excreted or released from the body.

In Generi Biotech, we have vast experience with qPCR testing in different matrices, most commonly in:

  • excreta (feces)
  • secreta (urine, saliva, nasopharyngeal fluids etc.)
  • skin-related tissue biopsies (pustules, sores, wounds)
Useful links
Recommended products
Duálně značené hydrolyzační sondy

Duálně značené hydrolyzační sondy Duálně značené hydrolyzační sondy

Technologie duálně značených hydrolyzačních sond (tzv. TaqMan® sondy) využívá 5 ́-3 ́ exonukleázové aktivity Taq DNA polymerázy ke štěpení duálně značené hydrolyzační sondy. Hydrolyzační sondy jsou značeny na 5´ konci fluorescenčním barvivem (reporterem) a na 3´ konci zhášečem (quencherem).

Recommended articles